IRFC updates on global medium term note programme
Posted On: 2021-02-01 11:38:12 (Time Zone: Arizona, USA)
Indian Railway Finance Corporation Limited (the Issuer or IRFC ) has recently updated and upsized its global medium term note programme (the Programme ), pursuant to which the aggregate principal amount of notes that may be issued under the Programme has been increased from USD2,000,000,000 to USD4,000,000,000. The Programme is listed on the Singapore Exchange Securities Trading Limited (SGX) and the India International Exchange (IFSC) Limited (INX).
Further, in connection with the above mentioned Programme, IRFC, rated Baa3 (Negative) / BBB- (Stable) / BBB- (Negative) by Moody s / S&P / Fitch, respectively, has mandated BNP PARIBAS, DBS Bank Ltd., HSBC, MUFG, SBICAP and Standard Chartered Bank as Joint Lead Managers and Joint Bookrunners to arrange a series of fixed income investor calls in Asia, Europe and U.S. commencing February 2nd 2021. A benchmark sized inte
Lee Cho-Hee Of MS Team, Wholly-Owned By Spackman Entertainment Group s Associated Company, Spackman Media Group, Stars In New SBS Variety Show BEAUTY AND THE BEAST Premiering In The First Half Of 2021
livenews.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livenews.co.nz Daily Mail and Mail on Sunday newspapers.
Lee Min‐jung of MS Team, Wholly-Owned by Spackman Entertainment Group s Associated Company, Spackman Media Group, Wins the Top Excellence Award at the 2020 APAN Star Awards
livenews.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livenews.co.nz Daily Mail and Mail on Sunday newspapers.
Power Finance Corporation Raises $500 Million Via Notes
moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.
(2)
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms
Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets
Sustainable growth and people development a priority for both companies
A French version of this release is also available
Quote from Gordon Bates, President and Head of Small Molecules, Lonza: NextPharma is an established and well-respected company, with extensive experience in oral and topical finished dosage forms. As such, it is the ideal buyer given the technologies available at the Ploermel and Edinburgh sites. We are confident that the capabilities and experience at the two sites are a complementary fit with NextPharma s